# Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors

> **NCT03991832** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 58 (estimated)

## Conditions studied

- Glioma
- Cholangiocarcinoma
- Solid Tumor
- IDH Mutation

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT03991832
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-12-31
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03991832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03991832, "Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03991832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*